Hormonal
Short-term vitamin D3 supplementation (120,000 IU every two weeks for 6 weeks) improves postprandial insulin sensitivity (measured by OGIS) in centrally obese, non-diabetic men, but does not affect fasting insulin sensitivity, lipid profiles, or blood pressure.
If you are a centrally obese man over 35 with low vitamin D, taking 120,000 IU of Vitamin D3 every two weeks for six weeks may help your body handle sugar after meals better. However, do not expect this to lower your fasting blood sugar, improve your cholesterol, or lower your blood pressure. It is a targeted intervention for postprandial sensitivity, not a general metabolic fix.
The trial indicates that vitamin D3 supplementation improves postprandial insulin sensitivity (OGIS) in apparently healthy men likely to have insulin resistance (centrally obese but non-diabetic)... No changes in secondary outcome measures (insulin secretion, basal indices of insulin sensitivity, blood pressure or lipid profile) were found with supplementation.
Why this rating
Double-blind, randomized, placebo-controlled trial (RCT) with a reasonably large sample size for the setting, though limited by short duration and drop-out rate.
Source
A double‐blind, randomized, placebo‐controlled trial of the short‐term effect of vitamin D<sub>3</sub> supplementation on insulin sensitivity in apparently healthy, middle‐aged, centrally obese men
Jitender Nagpal et al. · Diabetic Medicine · 2008
DOI 10.1111/j.1464-5491.2008.02636.x
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →